Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis

Gastroenterology

Volumn 147, Issue 6, 2014, Pages 1296-1307.e5

  Adedokun, Omoniyi J ^a   Sandborn, William J ^b   Feagan, Brian G ^c   Rutgeerts, Paul ^d   Xu, Zhenhua ^a   Marano, Colleen W ^a   Johanns, Jewel ^a   Zhou, Honghui ^a   Davis, Hugh M ^a   Cornillie, Freddy ^e   Reinisch, Walter ^f,g  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Janssen Biologics   (Netherlands)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti Tumor Necrosis Factor; Inflammatory Bowel Disease; Monoclonal Antibody; Pharmacokinetics

Indexed keywords

ALBUMIN; AZATHIOPRINE; CORTICOSTEROID; DRUG ANTIBODY; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PLACEBO; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HEALING; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REMISSION; SENSITIVITY AND SPECIFICITY; STEADY STATE; TREATMENT RESPONSE; ULCERATIVE COLITIS; BLOOD; CLINICAL TRIAL; COLITIS, ULCERATIVE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DRUG MONITORING; INTESTINE MUCOSA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG MONITORING; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84913534923     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.08.035     Document Type: Article

References (31)

1. REMICADE (infliximab) prescribing information (revised March 2013). Available at: http://www.remicade.com/shared/product/remicade/prescribing-information.pdf. Accessed: June 11, 2013.
2. P. Rutgeerts, W.J. Sandborn, and B.G. Feagan Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
3. M.A. Siddiqui, and J.L. Scott Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis Drug 66 2006 2179 2208
4. A.A. Fasanmade, O.J. Adedokun, and J. Ford Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis Eur J Clin Pharmacol 65 2009 1211 1228
5. A. Fasanmade, A. Olson, and W. Bao Relationship between infliximab pharmacokinetics and improvement in Crohn's disease Gastroenterology 122 Suppl 1 2002 A617 A618
6. A.A. Fasanmade, P. Marsters, and E. Munsanje Infliximab pharmacokinetics and improvement in fistulizing Crohn's disease Gastroenterology 124 Suppl 1 2003 A61
7. E.W. St. Clair, C.L. Wagner, and A.A. Fasanmade The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis Arthritis Rheum 46 2002 1451 1459
8. A.B. Gottlieb, S. Masud, and R. Ramamurthi Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris J Am Acad Dermatol 48 2003 68 75
9. I. Ordas, D.R. Mould, and B.G. Feagan Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms Clin Pharmacol Ther 91 2012 635 646
10. F. Baert, M. Noman, and S. Vermeire Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 2003 601 608
11. E.A. Maser, R. Villela, and M.S. Silverberg Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease Clin Gastroenterol Hepatol 4 2006 1248 1254
12. M. Bortlik, D. Duricova, and K. Malickova Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease J Crohns Colitis 7 2013 736 743
13. C.H. Seow, A. Newman, and S.P. Irwin Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis Gut 59 2010 49 54
14. C. Steenholdt, K. Bendtzen, and J. Brynskov Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease Scand J Gastroenterol 46 2011 310 318
15. K.W. Schroeder, W.J. Tremaine, and D.M. Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study N Engl J Med 317 1987 1625 1629
16. S.B. Hanauer, C.L. Wagner, and M. Bala Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease Clin Gastroenterol Hepatol 2 2004 542 553
17. W.J. Youden Index for rating diagnostic tests Cancer 3 1950 32 35
18. D. Mulleman, D. Chu Miow Lin, and E. Ducourau Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis Ther Drug Monitor 32 2010 232 236
19. E.W. St Clair, C.L. Wagner, and A.A. Fasanmade The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 46 2002 1451 1459
20. E. Pallagi-Kunstár, K. Farkas, and Z. Szepes Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease World J Gastroenterol 20 2014 5031 5035
21. W.J. Sandborn, B.G. Feagan, and C. Marano Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis Gastroenterology 146 2014 96 109
22. F. Cornillie, S.B. Hanauer, and R.H. Diamond Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial Gut 63 2014 1721 1727
23. A.A. Fasanmade, O.J. Adedokun, and A. Olson Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis Int J Clin Pharmacol Ther 48 2010 297 308
24. K. Karmiris, G. Paintaud, and M. Noman Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease Gastroenterology 137 2009 1628 1640
25. A. Cassinotti, and S. Travis Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review Inflamm Bowel Dis 15 2009 1264 1275
26. V. Casteele, A. Gils, and S. Singh Antibody response to infliximab and its impact on pharmacokinetics can be transient Am J Gastroenterol 108 2013 962 971
27. W. Afif, E.V. Loftus Jr., and W.A. Faubion Clinical utility of measuring infliximab and human antichimeric antibody concentrations in patients with inflammatory bowel disease Am J Gastroenterol 105 2010 1133 1139
28. R. Ariza-Ariza, F. Navarro-Sarabia, and B. Hernández-Cruz Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review Rheumatology (Oxford) 46 2007 529 532
29. S. Paul, E. Del Tedesco, and H. Marotte Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study Inflamm Bowel Dis 19 2013 2568 2576
30. C. Steenholdt, J. Brynskov, and O.O. Thomsen Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial Gut 63 2014 919 927
31. R. Khanna, B.D. Sattin, and W. Afif Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease Aliment Pharmacol Ther 38 2013 447 459